Evidence map›Paper›PMID 41591202›Full record

ReviewToxins2026

Strategies for Removal of Protein-Bound Uremic Toxins in Hemodialysis.

Joost C de Vries, João G Brás, Geert M de Vries, Jeroen C Vollenbroek, Fokko P Wieringa, Joachim Jankowski, Marianne C Verhaar, Dimitrios Stamatialis, Rosalinde Masereeuw, Karin G F Gerritsen

Abstract readReview
In one paragraph

Review in Toxins, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Joost C de VriesDepartment of Nephrology and Hypertension, University Medical Centre Utrecht, 3584 CX Utrecht, The Netherlands.
João G BrásDepartment of Nephrology and Hypertension, University Medical Centre Utrecht, 3584 CX Utrecht, The Netherlands.ORCID 0009-0000-7238-1998
Geert M de VriesDepartment of Nephrology and Hypertension, University Medical Centre Utrecht, 3584 CX Utrecht, The Netherlands.
Jeroen C VollenbroekDepartment of Nephrology and Hypertension, University Medical Centre Utrecht, 3584 CX Utrecht, The Netherlands.ORCID 0000-0002-0778-3509
Fokko P WieringaDepartment of Nephrology and Hypertension, University Medical Centre Utrecht, 3584 CX Utrecht, The Netherlands.ORCID 0000-0002-7759-7816
Joachim JankowskiAachen-Maastricht Institute for Cardiorenal Disease (AMICARE), University Hospital RWTH Aachen, 52074 Aachen, Germany.
Marianne C VerhaarDepartment of Nephrology and Hypertension, University Medical Centre Utrecht, 3584 CX Utrecht, The Netherlands.ORCID 0000-0002-3276-6428
Dimitrios StamatialisAdvanced Organ Bioengineering and Therapeutics, Faculty of Science and Technology, Technical Medical Centre, University of Twente, P.O. Box 217, 7500 AE Enschede, The Netherlands.ORCID 0000-0002-2298-2442
Rosalinde MasereeuwDivision of Pharmacology, Utrecht Institute for Pharmaceutical Sciences, Utrecht University, 3584 CG Utrecht, The Netherlands.ORCID 0000-0002-1560-1074
Karin G F GerritsenDepartment of Nephrology and Hypertension, University Medical Centre Utrecht, 3584 CX Utrecht, The Netherlands.ORCID 0000-0002-1917-6255

Funding

Dutch national growth fund (NXTGEN HighTech) Biomed04 'Artificial Organs' projectDutch organization for Scientific Research (NWO-TTW) 20775European Commission (KIDNEW, HORIZON-EIC-2022 Pathfinder program) 101099092European Renal Association-European Dialysis Transplantation Association (ERA-EDTA) European Uremic Toxin working group (EUTox)Kidney Innovation Accelerator KidneyX prize Project "MI-TRAM: Smart Module for Implantable, Wearable, Portable, or Bedside Artificial Kidneys"Nierstichting PIONIER+ 22OP+059
6 · The paper itself

Abstract

The removal of protein-bound uremic toxins (PBUTs) from the blood of kidney failure patients with conventional dialysis is limited. However, as their harmful effects and association with morbidity and mortality in dialysis patients are increasingly recognized, PBUTs have become important therapeutic targets. In this review, PBUT removal with current state-of-the-art dialysis technologies and future perspectives are discussed. Strategies to enhance PBUT clearance include methods that interfere with PBUT-albumin binding, such as chemical displacers, high ionic strength, pH changes, or electromagnetic fields, thereby increasing the free fraction available for dialysis. While these methods have shown promise in vitro, and some also in vivo, long-term safety data are lacking. PBUT removal can also be increased by adsorption, either directly via hemoperfusion, or indirectly, e.g., via sorbents incorporated in a mixed-matrix membrane or dissolved in the dialysate. In the kidney, PBUTs are secreted in the proximal tubules; hence, a cell-based bioartificial kidney (BAK) that secretes PBUTs is proposed as an add-on to current dialysis. Yet both PBUT adsorption strategies and, in particular, BAKs face considerable challenges in upscaling and mass production at acceptable costs. In conclusion, many novel technologies are under development, all requiring further (pre)clinical testing and upscaling before these strategies can be applied in the clinic.

Indexed as

Renal DialysisUremiaUremic ToxinsAdsorptionAnimalsHumansProtein BindingUremic Toxinsadsorptionbioartificial kidneyhemodialysisprotein-bound uremic toxinsrenal replacement therapytissue engineering

Identifiers

PMID41591202
PMCPMC12846473

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.